ArticleHuman brain mapping2023
Magnetic resonance evidence of increased iron content in subcortical brain regions in asymptomatic Alzheimer's disease.
Article in Human brain mapping, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Multimodal MRI Reveals Cerebral and Vascular Amyloid-Driven Myeloarchitectural Disorganization in a Mouse Model of Alzheimer's Disease.NMR in biomedicine · 2026Article
- Role and mechanisms of ferroptosis in cognitive impairment: From molecular pathways to therapeutic targets (Review).International journal of molecular medicine · 2026Review
- Imaging markers of neuroinflammation in aging and Alzheimer's disease and related dementia: A comprehensive review.Neuroscience and biobehavioral reviews · 2025Review
- Evaluation of iron deposition in diabetic kidney disease using the kidney-to-muscle signal intensity ratio on routine MRI T2WI sequences.Abdominal radiology (New York) · 2025Article
- Ferroptosis in Cognitive Impairment Associated with Diabetes and Alzheimer's Disease: Mechanistic Insights and New Therapeutic Opportunities.Molecular neurobiology · 2025Review
- Accelerated model-based T1, T2* and proton density mapping using a Bayesian approach with automatic hyperparameter estimation.Magnetic resonance in medicine · 2025Article
- Change in transverse relaxation rates (RHuman brain mapping · 2025Article
- Do toenail manganese and iron levels reflect brain metal levels or brain metabolism in welders?Neurotoxicology · 2024Article
- Iron homeostasis in older adults: balancing nutritional requirements and health risks.The journal of nutrition, health & aging · 2024Review
- Review
- Review
- R-Mixup: Riemannian Mixup for Biological Networks.KDD : proceedings. International Conference on Knowledge Discovery & Data Mining · 2023Article
- Magnetic resonance evidence of increased iron content in subcortical brain regions in asymptomatic Alzheimer's disease.Human brain mapping · 2023Article
- Protective Roles of Hydrogen Sulfide in Alzheimer's Disease and Traumatic Brain Injury.Antioxidants (Basel, Switzerland) · 2023Review
- Iron chelators as a therapeutic option for Alzheimer's disease-A mini-review.Frontiers in aging · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
While iron over-accumulation has been reported in late stage Alzheimer's disease (AD), whether this occurs early in the asymptomatic stage of AD remains unknown. We aimed to assess brain iron levels in asymptomatic AD using quantitative MR relaxometry of effective transverse relaxation rate (R2*) and longitudinal relaxation rate (R1), and recruited 118 participants comprised of three groups including healthy young participants, and cognitively normal older individuals without or with positive AD biomarkers based on cerebrospinal fluid (CSF) proteomics analysis. Compared with the healthy young group, increased R2* was found in widespread cortical and subcortical regions in the older groups. Further, significantly higher levels of R2* were found in the cognitively normal older subjects with positive CSF AD biomarker (i.e., asymptomatic AD) compared with those with negative AD biomarker in subcortical regions including the left and right caudate, left and right putamen, and left and right globus pallidus (p < .05 for all regions), suggesting increased iron content in these regions. Subcortical R2* of some regions was found to significantly correlate with CSF AD biomarkers and neuropsychological assessments of visuospatial functions. In conclusion, R2* could be a valuable biomarker for studying early pathophysiological changes in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.